tradingkey.logo

60 Degrees Pharmaceuticals Inc

SXTP

1.330USD

0.000
Horarios del mercado ETCotizaciones retrasadas 15 min
1.96MCap. mercado
PérdidaP/E TTM

60 Degrees Pharmaceuticals Inc

1.330

0.000
Más Datos de 60 Degrees Pharmaceuticals Inc Compañía
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Información de la empresa
Símbolo de cotizaciónSXTP
Nombre de la empresa60 Degrees Pharmaceuticals Inc
Fecha de salida a bolsaJul 12, 2023
Director ejecutivoDr. Ll S. Dow, Ph.D.
Número de empleados3
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 12
Dirección1025 Connecticut Avenue Nw
CiudadWASHINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal20036
Teléfono12023275422
Sitio Webhttps://60degreespharma.com/
Símbolo de cotizaciónSXTP
Fecha de salida a bolsaJul 12, 2023
Director ejecutivoDr. Ll S. Dow, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
8.82K
+131.03%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Operating Officer
Chief Operating Officer
4.54K
+22.47%
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
+0.43%
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
234.00
+0.43%
Mr. Patrick Gaynes
Mr. Patrick Gaynes
IR Contact Officer
IR Contact Officer
--
--
Dr. Ll S. Dow, Ph.D.
Dr. Ll S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
8.82K
+131.03%
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
5.27K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Operating Officer
Chief Operating Officer
4.54K
+22.47%
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
234.00
+0.43%
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
234.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
234.00
+0.43%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 26 de jul
Actualizado: sáb., 26 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Heights Capital Management, Inc.
8.37%
Orca Capital GmbH
5.15%
Intracoastal Capital, L.L.C.
1.41%
Knight Therapeutics, Inc.
1.05%
Dow (Geoffrey S)
0.62%
Other
83.40%
Accionistas
Accionistas
Proporción
Heights Capital Management, Inc.
8.37%
Orca Capital GmbH
5.15%
Intracoastal Capital, L.L.C.
1.41%
Knight Therapeutics, Inc.
1.05%
Dow (Geoffrey S)
0.62%
Other
83.40%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
14.04%
Corporation
2.46%
Individual Investor
1.22%
Investment Advisor/Hedge Fund
0.37%
Hedge Fund
0.05%
Other
81.86%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
28
103.36K
3.20%
+13.74K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
2023Q3
18
63.13K
66.75%
+44.65K
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Knight Therapeutics, Inc.
33.90K
2.3%
+14.67K
+76.26%
Sep 30, 2024
Dow (Geoffrey S)
19.97K
1.36%
+4.38K
+28.07%
Jun 09, 2025
UBS Financial Services, Inc.
16.19K
1.1%
+12.11K
+296.57%
Mar 31, 2025
Geode Capital Management, L.L.C.
11.92K
0.81%
+11.92K
--
Mar 31, 2025
Xu (Cheryl)
8.82K
0.6%
+5.00K
+131.03%
Jun 03, 2025
Miller (Tyrone)
5.27K
0.36%
--
--
Mar 27, 2025
Landon (Kristen)
4.54K
0.31%
+833.00
+22.47%
Mar 27, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
Fecha
Tipo
Relación
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Feb 20, 2025
Merger
5<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
Aug 06, 2024
Merger
12<1
KeyAI